Building High-Performance Off-the-shelf Therapeutic Vaccines Based on Shared TSAs from the Cryptic Genome
Time: 8:50 am
day: Day One
Details:
- Epitopea is exploiting a new family of mass spec identified wild-type TSAs derived from so-called non-coding DNA that represent the major opportunity for T cell-mediated control of tumours
- Configured into a LNP-mRNA vaccine, the mouse counterparts of these antigens control tumour growth as single agents
- We are configuring human cryptic TSAs into highly effective cancer vaccines, where each class I TSAs within can be confirmed to be presented by mass spectroscopy
